Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2022 | Developments in targeted lung cancer therapies

Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, describes recent advances in targeted therapies for lung cancer. Whilst previous targets have primarily been EGFR, ALK, ROS1, there has been a recent increase in druggable mutations including NTRK, BRAF, RET, HER2, KRAS G12C, and MET exon 14 skipping mutations. Dr Baijal additionally highlights at use of novel targeted therapies in the adjuvant setting, following the approval of osimertinib based on the data from the Phase III ADAURA (NCT02511106) trial. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.

Disclosures

Dr Baijal has received honoraria from: Abbvie, Amgen, AstraZeneca, Boehringer Ingleheim, Bristol Myers-Squibb, Chugai, Daiichi Sankyo, FoundationOne, GlaxoSmithKline, Janssen, Lilly, Merck Serono, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi and Takeda.